Eflornithine for treating high-risk neuroblastoma with complete or partial response after immunotherapy [ID4060]
In development
Reference number: GID-TA10990
Expected publication date: TBC
Please note that following conversations between NICE and the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early September 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-November 2024. Draft scope consultation will be issued in late July 2024.